Longevity biomarkers: a critical guide to biological age,

Longevity biomarkers: what they really measure (and what they don’t)

The idea of “longevity” as a metric is seductive because it promises order: a number, a curve, a before/after. But aging is not a single process. It is a convergence of systems—vascular, metabolic, immune, neuromuscular—that can deteriorate at different speeds, for different reasons, with signals that are often indirect. This is why longevity biomarkers, in practice, are not measures of the future: they are descriptions of present physiological burden, functional reserve, and the statistical likelihood of certain outcomes.

What we call “biological age” is often a cultural shortcut: a narrative of control in a domain that by its nature remains probabilistic. Measuring can be useful—very useful even—but only if we know what we are measuring, which system is speaking, how much noise there is in the signal, and what we can realistically change.

Why “longevity” is not a metric: the problem of biological age as a simplification

The central tension is this: we want a single measure because it reduces uncertainty; the biology of aging, by contrast, is multi-domain and non-linear. “Living a long time” (lifespan) and “living a long time with good function” (healthspan) are not the same thing. The former concerns duration; the latter concerns the quality and continuity of capacities: walking, thinking, recovering, maintaining autonomy. In between there is a third level, often more measurable: short- to medium-term risk of events and complications (cardiovascular, metabolic, renal, infectious).

Many biomarkers presented as “longevity” markers are actually proxies of burden: they capture how much a system is operating out of balance, or how exposed it is to cumulative stresses. An elevated hs-CRP is not “accelerated aging” in any direct sense: it is a signal that, at that moment, there is an inflammatory tone higher than desirable, for reasons that may be trivial (a recent flu) or structural (visceral adiposity, periodontitis, steatosis, sleep disorders). A high ApoB is not a sentence, but it describes atherogenic lipoprotein traffic that, over time, increases the probability of atherosclerosis.

To stay clear-headed, it helps to distinguish three families:

1) Risk biomarkers (events): measures that correlate well with the probability of clinical outcomes (e.g. blood pressure, ApoB/non-HDL, HbA1c, albuminuria).
2) Function biomarkers (capacity): measures that describe biologically “useful” reserve and performance (VO₂max, strength, walking speed, waist circumference as a proxy for abdominal adiposity).
3) Integrity / “biological age” biomarkers (patterns): model outputs (epigenetics, glycans, proteomics) that capture statistical signatures associated with age and risk, but do not measure a single causal mechanism.

Within these families, one rule applies that is rarely stated: your personal baseline matters. There is day-to-day biological variability; there are fluctuations due to sleep, infections, the menstrual cycle, training, stress; and there is regression to the mean (an extreme value will often tend to “normalize” at the next check even without intervention). Measurement becomes useful when it guides sound clinical and behavioral decisions—not when it fuels a hunt for micro-variations.

If you are interested in the cultural and methodological context behind this “hunger for metrics,” it is also worth reading: BIOHACKING: A SCIENTIFIC GUIDE TO OPTIMIZING BODY AND MIND. Not to adopt a stance, but to recognize its biases.

A practical framework: what makes a biomarker truly informative over time

A biomarker is informative when it meets several criteria at once. It is not enough to “be measurable”: it must improve the quality of decisions. In practice, four properties matter more than any promise:

• Predictiveness of outcomes: how strongly that value is associated with real events (mortality, heart attacks, stroke, diabetes, kidney failure, frailty).
• Analytical robustness: how standardized and comparable the test is (labs, methods, units).
• Biological repeatability: how much it changes without a real change in state (noise).
• Sensitivity to the “right” kind of change: how well it reflects stable physiological improvements and not just transient fluctuations.

Then there are confounders, which are not minor details: recent infections, vaccines, intense training, sleep deprivation, alcohol, medications (corticosteroids, statins, diuretics, contraceptives), rapid weight loss, prolonged fasting, the menstrual cycle. Ignoring them produces reading errors: attributing to “metabolism” what is actually the flu, or to “longevity” what is actually training overload.

A panel should be read as a constellation: coherent patterns across different markers are more reliable than any single value. The direction and speed of change also matter: an HbA1c that slowly declines and stays stable is more informative than a CRP that fluctuates. There is no universal “optimal” value outside of context: age, sex, family history, comorbidities, medications, and clinical goals all change the interpretation.

It is also useful to think in terms of time horizon:

• Rapid (days–weeks): hs-CRP, fasting glucose (very sensitive to stress and sleep).
• Intermediate (weeks–months): lipids, blood pressure (depending on method), liver enzymes.
• Slow (months): HbA1c (memory ~8–12 weeks), actual body composition.
• Very slow/derived: epigenetic clocks (and still sensitive to states such as inflammation and weight loss, which can “move” the model without being equivalent to rejuvenation).

When should you repeat a test? Three cases: (1) to confirm an abnormality, (2) after realistic interventions (often 8–12 weeks), (3) when symptoms or clinical conditions change. Repeating too often increases noise and measurement anxiety.

Table — reading biomarkers as families (not as scores)

Inflammation, immunity, and systemic burden: useful signals, but often non-specific

“Inflammaging” is a good term when it does not become a lazy label. It describes a tendency: with age and with certain exposures (visceral adiposity, sedentary living, chronic stress, disrupted sleep, persistent infections, periodontal disease), low-grade inflammatory tone increases. But clinically, the right question is not “am I inflamed?”—it is where the signal is coming from and for how long.

hs-CRP is a perfect example: it is sensitive and useful, but not specific. It can rise because of trivial infections, trauma, dental procedures, very intense training, or subclinical inflammation. It becomes informative when it is persistently elevated and accompanied by coherent patterns: high waist circumference, high triglycerides, low HDL, higher blood pressure, suspected steatosis, poor sleep. Again: this is not “longevity,” it is systemic burden.

A complete blood count with differential can provide rough clues. The neutrophil-to-lymphocyte ratio (NLR) is sometimes used as an indicator of immune stress: it rises in many conditions (infections, physiological stress, smoking, inflammation). It is easy to overinterpret. It can be a flag, not a diagnosis.

Ferritin is a hybrid marker: it represents iron stores, but it is also an acute-phase protein. A “high” ferritin may mean elevated iron, inflammation, steatosis, metabolic syndrome, alcohol, or combinations of these. A “low” ferritin may indicate iron deficiency, but it should be read alongside a blood count, transferrin/saturation, and context (losses, diet, absorption). This is one of the places where naive interpretation (“more is better”) causes harm.

Albumin and total protein, in some contexts, reflect general status and chronic inflammation, but they are influenced by hydration, liver function, protein loss, and should not be used as a shortcut for “health status.”

The editorial rule here is simple: these markers require clinical context. Symptoms, oral health, sleep patterns, abdominal adiposity, recurrent infections, medications—they are part of the “laboratory” just as much as the vials are.

Table — inflammatory/immune markers: what they say and what they don’t say

Cardiometabolic: where risk is measured best, and why it is central to real longevity

If we have to choose one axis along which measurement offers the best signal-to-noise ratio for “real longevity,” it is the cardiovascular-metabolic axis. Not because it is trendy, but because of epidemiology: a huge share of mortality and disability runs through atherosclerosis, hypertension, diabetes, steatosis, and their complications. Here biomarkers are not perfect, but they are among the most “actionable”: they predict outcomes and guide decisions with a relatively high level of evidence.

Lipids. LDL-C is useful, but it describes the cholesterol content inside particles, not how many atherogenic particles are circulating. ApoB approximates the number of atherogenic particles (LDL, VLDL remnants, IDL): at the same LDL-C, ApoB can differ and change risk. Non-HDL is another practical way of capturing total “atherogenic” cholesterol. Triglycerides and HDL are not “good/bad” in a moral sense: they are often signals of lipoprotein metabolism and insulin sensitivity.

Blood pressure. This is a functional biomarker: it tells the story of hemodynamic load and vascular stress. It is also one of the easiest to distort with poor measurement. It requires repetition, method, and often home readings: “office blood pressure” may lie because of anxiety or, conversely, conceal masked hypertension.

Glucose. Fasting glucose is noisy (sleep, stress, training). Fasting insulin may add information but must be handled with caution (variability, methods). HOMA-IR is a proxy, not the truth. HbA1c is more stable: a glycemic memory over weeks. It does not say everything (anemia, hemoglobinopathies, and special conditions alter it), but it is an important reference point.

Liver and steatosis. ALT/AST and especially GGT may signal liver strain or metabolic burden, often linked to insulin resistance and visceral adiposity. They are not specific: alcohol, medications, exercise, hepatitis all change the picture. But within a coherent metabolic pattern, they become informative.

Kidney/vascular. Creatinine and eGFR describe kidney function (with limitations related to muscle mass). When available, the urinary albumin-to-creatinine ratio (ACR) is an early signal: it may indicate endothelial/kidney damage and is associated with cardiovascular risk.

The key point is integration: a “pattern of insulin resistance” often appears as high triglycerides, low HDL, increased waist circumference, higher blood pressure, shifted ALT/GGT, and rising HbA1c. No single number, on its own, contains the whole story.

Table — cardiometabolic: predictive value and pitfalls

For a broader framing of mechanisms and limits when discussing “repair” and aging, without narrative shortcuts, this is useful: Cellular aging biology: mechanisms, signals, and the limits of biological “repair”.

Function and reserve: biomarkers that speak to “capacity,” not just risk

Much of preventive medicine is (rightly) oriented toward risk: what increases the probability of future events. But lived longevity—healthspan—depends crucially on functional reserve: how much capacity remains when inevitable stresses arrive (infections, accidents, procedures, periods of inactivity). Here some markers are not lab tests, and precisely for that reason they are often more “causal” and less noisy.

Cardiorespiratory fitness (measured or estimated VO₂max; exercise testing or submaximal tests) is among the strongest predictors of mortality in many studies. Not because it is a talisman, but because it integrates multiple systems: heart, lungs, muscle, mitochondria, autonomic regulation, and the capacity to transport and use oxygen. Improving it takes time: this slowness is an advantage, because it makes the illusion of transient change less likely.

Strength and power (handgrip, sit-to-stand, walking speed) are indicators of sarcopenia and resilience. Here too, the interest is not aesthetic: it is autonomy, fall risk, recovery from hospitalization, the ability to “get back on your feet” after an event.

Body composition goes beyond BMI. Waist circumference or waist-to-height ratio capture abdominal adiposity better, which is often more closely linked to metabolic risk than total weight. Lean mass matters not only for “metabolism,” but for reserve: available amino acids, stability, capacity for movement.

Sleep and circadian rhythm are not a gadget chapter: they are regulators of the autonomic and metabolic axis. But the proxies should be chosen soberly. Wearables and HRV can be observation tools, not diagnoses. Often concrete signals such as blood pressure, daytime sleepiness, perceived sleep quality, regularity of schedules, and daytime performance offer more guidance than a single score.

On nutrition and homeostasis: vitamin D may be an indicator of exposure and status (with limits and seasonality), while B12/folate become relevant in specific contexts (restrictive diets, malabsorption, certain medications). They are not “longevity shortcuts”: they are pieces of a physiology that, if deficient, reduces reserve.

Table — functional reserve: measures, value, confounders

For a more methodological discussion of what it means to “optimize” without turning health into a dashboard, this may also help: Biohacking: a scientific guide to optimizing body and mind.

Biological clocks and “age” tests: epigenetics, glycans, proteomics—promises, uses, and limits

A “biological age” test does not measure aging the way a thermometer measures temperature. It measures a pattern: a statistical model trained to recognize signatures associated with chronological age or clinical outcomes. That does not make it useless, but it changes its epistemic status: it is not a thermometer, it is a composite index.

Epigenetic clocks are based on DNA methylation: a molecular trace that reflects exposures, inflammatory state, environment, and metabolic history. Some clocks correlate with risk and mortality at the population level and, in research contexts, can be interesting tools. But individual interpretation is fragile for three reasons:

1) Variability across models and laboratories: different clocks may give different answers for the same person.
2) Sensitivity to rapid changes: weight loss, inflammation, stress can shift the output. This may represent a real change in state, but it does not automatically equal structural “rejuvenation.”
3) Reification: turning a number into biological identity (“I am older/younger”) and then chasing it. The psychological risk is not secondary: an unstable metric can shift the focus from sustainable behaviors to obsessive control.

Glycans, proteomics, and metabolomics promise granularity: describing dynamic states with many variables. They are fascinating and probably relevant in the future, but today they suffer from limitations in standardization, individual interpretation, and clinical availability. They may be closer to “state” than to “structure”: useful for research or for well-contextualized longitudinal pathways, less so as everyday guidance.

The Crionlab criterion is pragmatic: a test is useful if it improves concrete decisions (blood pressure, lipoprotein risk, body composition, fitness, sustainable sleep) and if it does not replace clinical fundamentals. If it becomes a scoring game, it produces noise: biological and mental.

Building a responsible personal panel: frequency, context, and the right questions to ask your doctor

A sensible “longevity” panel is not the one that contains more tests, but the one that reduces uncertainty in proportion to your actual risk. The best approach is tiered: basic (regular, comparable over time) and targeted (based on age, family history, symptoms, conditions, treatment).

A reasonable basic panel, often annual (to be discussed with your doctor), includes: properly measured blood pressure; a lipid profile with ApoB if possible (or non-HDL as an alternative); glucose and HbA1c; complete blood count; creatinine with eGFR; ALT/AST/GGT; hs-CRP. Depending on context: urinary ACR, TSH, ferritin and iron status, vitamin D, B12/folate—but only if there is a clinical reason, not for collecting purposes.

Non-lab measures deserve the same status: waist circumference, cardiorespiratory fitness testing, strength. They have one advantage: they are often closer to what, in real life, we call “feeling well.” And they change with interventions that, if sustainable, tend to improve multiple systems at once.

Interpretation: an isolated variation requires replication. Trends across 2–3 measurements, in the same context (same laboratory when possible, same conditions), are more informative. If a value is out of range, the first question is not “how do I lower it?” but “is it real, persistent, consistent with other signals, and clinically meaningful for me?”

When to investigate further: persistent signals—repeated high CRP, elevated ALT/GGT, elevated ApoB, elevated ACR, blood pressure above target—or symptoms, or an important family history. This is where biomarkers become a shared language: a basis for better medical conversations, not a performance dashboard.

Measuring, in this framework, is not a strategy of total control. It is a way to see where the body is paying a cost: in lipoprotein traffic, blood pressure burden, inflammatory tone, aerobic reserve, body composition. Longevity remains emergent: an outcome of many trajectories. Biomarkers are partial maps—useful when they teach us to think in systems.

FAQ

What are the most reliable longevity biomarkers today?
Those with the strongest link to clinical outcomes and good standardization: blood pressure, lipid markers (especially ApoB or non-HDL), HbA1c, indicators of kidney function (creatinine/eGFR), and measures of fitness and strength. “Reliable” does not mean perfect: it means useful for estimating risk and guiding realistic choices over time.

Can a “biological age” test tell me how many years I will live?
No. Biological age tests are statistical models that estimate a pattern associated with age and risk, but they do not provide an individual prediction of lifespan. They may be informative as a contextualized longitudinal measure, but they do not replace solid clinical markers and medical evaluation.

How often does it make sense to check biomarkers?
It depends on personal risk, age, family history, medications, and symptoms. For many people an annual panel is sufficient; if a concrete change is introduced (weight, physical activity, therapy), it often makes sense to reassess after 8–12 weeks for some markers and after 3–6 months for others. Repeating tests too frequently increases noise and measurement anxiety.

If hs-CRP is high, does it mean I am aging faster?
Not necessarily. hs-CRP is a sensitive but not very specific indicator: it can rise because of infections, trauma, physiological stress, or intense training. If it remains persistently elevated, it may signal low-grade inflammation and increased cardiometabolic risk; it should be interpreted in context and, often, confirmed with a repeat measurement.

Why is ApoB considered more informative than LDL?
LDL-C measures the cholesterol content inside LDL particles; ApoB approximates the number of atherogenic particles (each carries one ApoB). At the same LDL-C, a higher number of particles may increase risk. It is not a “new hack”: it is a more direct way of describing the lipoprotein traffic involved in atherosclerosis.

Is it possible to “improve” biomarkers without truly improving health?
Yes. Some values can change because of transient effects (rapid weight loss, extreme restriction, acute stress, dehydration) or because of short-term shifts that do not reflect a stable improvement in physiology. This is why trends, coherence across markers, and measures of function (blood pressure, fitness, body composition) matter.

Are wearables (HRV, sleep) longevity biomarkers?
They are indirect signals of autonomic regulation and load/recovery, not clinical biomarkers of longevity. They can be useful for noticing patterns (insufficient sleep, stress, overload), but they come with variability and artifacts. They should be treated as observation tools, not diagnoses.